Conditions and drugs interfering with thyroxine absorption

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 23, Issue 6, 2009, Pages 781-792

  Liwanpo, Llanyee ^a   Hershman, Jerome M ^a  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

hypothyroidism; interfering drugs; levothyroxine; malabsorption; thyroxine absorption

Indexed keywords

ALUMINUM DERIVATIVE; ALUMINUM HYDROXIDE; AMIODARONE; ANTACID AGENT; BILE ACID SEQUESTRANT; CALCIUM ACETATE; CALCIUM CARBONATE; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; ESOMEPRAZOLE; FERROUS SULFATE; LANSOPRAZOLE; LANTHANUM CARBONATE; LEVOTHYROXINE; MAGNESIUM HYDROXIDE; OMEPRAZOLE; PANTOPRAZOLE; PHOSPHATE BINDING AGENT; PLACEBO; PROTON PUMP INHIBITOR; RALOXIFENE; SEVELAMER; SIMETHICONE; SUCRALFATE; TETRAHYDROLIPSTATIN; THYROXINE; THYROXINE I 131; UNINDEXED DRUG; WARFARIN;

ABSORPTION; AREA UNDER THE CURVE; ATROPHIC GASTRITIS; BODY TEMPERATURE DISORDER; CELIAC DISEASE; CLINICAL TRIAL; COFFEE; COLD INTOLERANCE; DIETARY FIBER; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; DUODENUM ULCER; ENTERITIS; FATIGUE; FOOD INTAKE; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HELICOBACTER INFECTION; HUMAN; HYPOTHYROIDISM; LACTOSE INTOLERANCE; LETHARGY; MALABSORPTION; NODULAR GOITER; NONHUMAN; REVIEW; THYROID CANCER; THYROID DISEASE;

ALUMINUM HYDROXIDE; ANIMALS; ANTACIDS; BIOLOGICAL AVAILABILITY; CALCIUM CARBONATE; CELIAC DISEASE; COFFEE; DIETARY FIBER; DRUG INTERACTIONS; FEMALE; FOOD; GASTRITIS, ATROPHIC; HELICOBACTER INFECTIONS; HUMANS; INTESTINAL ABSORPTION; LACTOSE INTOLERANCE; MALABSORPTION SYNDROMES; THYROXINE;

EID: 71749087074     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2009.06.006     Document Type: Review

References (45)

1. Benvenga S., Bartolone L., Squadrito S., et al. Delayed intestinal absorption of levothyroxine. Thyroid 5 (1995) 249-253
2. Azizi F., Belur R., and Albano J. Malabsorption of thyroid hormones after jejunoileal bypass for obesity. Annals of Internal Medicine 90 (1979) 941-942
3. Topliss D.J., Wright J.A., and Volpé R. Increased requirement for thyroid hormone after a jejunoileal bypass operation. Canadian Medical Association Journal 123 (1980) 765-766
4. Bevan J.S., and Munro J.F. Thyroxine malabsorption following intestinal bypass surgery. International Journal of Obesity 10 (1986) 245-246
5. Stone E., Leiter L.A., Lambert J.R., et al. L-thyroxine absorption in patients with short bowel. The Journal of Clinical Endocrinology and Metabolism 59 (1984) 139-141
6. Vanderschueren-Lodeweyckx M., Eggermont E., Cornette C., et al. Decreased serum thyroid hormone levels and increased TSH response to TRH in infants with celiac disease. Clinical Endocrinology (Oxford) 6 (1977) 361-367
7. Csako G., McGriff N.J., Rotman-Pikielny P., et al. Exaggerated levothyroxine malabsorption due to calcium carbonate supplementation in gastrointestinal disorders. Annals of Pharmacotherapy 35 (2001) 1578-1583
8. Hays M.T. Absorption of oral thyroxine in man. The Journal of Clinical Endocrinology and Metabolism 28 (1968) 749-756
9. Read D.G., Hays M.T., and Hershman J.T. Absorption of oral thyroxine in hypothyroid and normal man. The Journal of Clinical Endocrinology and Metabolism 30 (1970) 798-799
10. Hasselström K., Siersbaek-Nielsen K., Lumholtz I.B., et al. The bioavailability thyroxine and 3,5,3′-triiodothyronine in normal subjects and in hyper- and hypothyroid patients. Acta Endocrinologica (Copenh) 110 (1985) 483-486
11. Greenstadt M.A., Spencer C.A., Lum S.M.C., et al. Non-isotopic method for determination of oral thyroxine absorption. In: Gueriguian J.L., Bransome E.D., and Outschoorn A.S. (Eds). Hormone drugs: proceedings of the FDA-USP workshop on drug and reference standards for insulins, somatropins, and thyroid-axis hormones (1982), United States Pharmacopeial Convention Inc, Rockville 534-539
12. Nicoloff J.T., Low J.C., Dussault J.H., et al. Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. The Journal of Clinical Investigation 51 (1972) 473-483
13. Wenzel K.W., and Kirschsieper H.E. Aspects of the absorption of oral L-thyroxine in normal man. Metabolism 26 (1977) 1-8
14. Liel Y., Harman-Boehm I., and Shany S. Evidence for a clinically important adverse effect of fiber-enriched diet on the bioavailability of levothyroxine in adult hypothyroid patients. The Journal of Clinical Endocrinology and Metabolism 81 (1996) 857-859
15. Chiu A.C., and Sherman S.I. Effects of pharmacological fiber supplements on levothyroxine absorption. Thyroid 8 (1998) 667-671
16. Benvenga S., Bartolone L., Pappalardo M.A., et al. Altered intestinal absorption of L-thyroxine caused by coffee. Thyroid 18 (2008) 293-301
17. D'Estève-Bonetti L., Bennet A.P., Malet D., et al. Gluten-induced enteropathy (coeliac disease) revealed by resistance to treatment with levothyroxine and alfacalcidol in a sixty-eight-year-old patient: a case report. Thyroid 12 (2002) 633-636
18. Silva C.M., and Souza M.V. Autoimmune hypothyroidism nonresponsive to high doses of levothyroxine and severe hypocalcemia. Arquivos Brasileiros de Endocrinologia e Metabologia 49 (2005) 599-603
19. Caputo M., Brizzolara R., Schiavo M., et al. Occurrence of overt celiac disease in the elderly following total thyroidectomy. Journal of Endocrinological Investigation 29 (2006) 831-833
20. McDermott J.H., Coss A., and Walsh C.H. Celiac disease presenting as resistant hypothyroidism. Thyroid 15 (2005) 386-388
21. Muñoz-Torres M., Varsavsky M., and Alonso G. Lactose intolerance revealed by severe resistance to treatment with levothyroxine. Thyroid 16 (2006) 1171-1173
22. Centanni M., Gargano L., Canettieri G., et al. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. The New England Journal of Medicine 354 (2006) 1787-1795
23. Phillips W.A., Schultz J.R., and Stafford W.W. Effects of colestipol hydrochloride on drug absorption in the rat. I. Aspirin, L-thyroxine, phenobarbital, cortisone, and sulfadiazine. Journal of Pharmaceutical Sciences 63 (1974) 1097-1101
24. Northcutt R.C., Stiel J.N., Hollifield J.W., et al. The influence of cholestyramine on thyroxine absorption. The Journal of the American Medical Association 208 (1969) 1857-1861
25. Weitzman S.P., Ginsburg K.C., and Carlson H.E. Colesevelam hydrochloride and lanthanum carbonate interfere with the absorption of levothyroxine. Thyroid 19 (2009) 77-79
26. Daiichi Sankyo, Inc. Welchol(r) prescribing information. Available from: www. Welchol.com/pdf/Welchol_PI.pdf.
27. Campbell R.C., Hasinoff B.B., Stalts H., et al. Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism. Annals of Internal Medicine 117 (1992) 1010-1013
28. Shakir K.M., Chute J.P., Aprill B.S., et al. Ferrous sulfate-induced increase in requirement for thyroxine in a patient with primary hypothyroidism. Southern Medical Journal 90 (1997) 637-639
29. Sherman S.I., Tielens E.T., and Ladenson P.W. Sucralfate causes malabsorption of L-thyroxine. American Journal of Medicine 90 (1994) 531-535
30. Havrankova J., and Lahaie R. Levothyroxine binding by sucralfate. Annals of Internal Medicine 117 (1992) 445-446
31. Campbell J.A., Schmidt B.A., and Bantle J.P. Sucralfate and the absorption of L-thyroxine. Annals of Internal Medicine 121 (1994) 152
32. Sperber A.D., and Liel Y. Evidence for interference with the intestinal absorption of levothyroxine sodium by aluminum hydroxide. Archives of Internal Medicine 152 (1992) 183-184
33. Liel Y., Sperber A.D., and Shany S. Nonspecific intestinal adsorption of levothyroxine by aluminum hydroxide. American Journal of Medicine 97 (1994) 363-365
34. Mersebach H., Rasmussen A.K., Kirkegaard L., et al. Intestinal adsorption of levothyroxine by antacids and laxatives: case stories and in vitro experiments. Pharmacology & Toxicology 84 (1999) 107-109
35. Schneyer C.R. Calcium carbonate and reduction of levothyroxine efficacy. [Letter]. The Journal of the American Medical Association 279 (1998) 750
36. Singh N., Singh P.N., and Hershman J.M. Effect of calcium carbonate on the absorption of levothyroxine. The Journal of the American Medical Association 283 (2000) 2822-2825
37. Singh N., Weisler S.L., and Hershman J.M. The acute effect of calcium carbonate on the intestinal absorption of levothyroxine. Thyroid 11 (2001) 967-971
38. Diskin C.J., Stokes T.J., Dansby L.M., et al. Effect of phosphate binders upon TSH and L-thyroxine dose in patients on thyroid replacement. International Urology and Nephrology 39 (2007) 599-602
39. John-Kalarickal J., Pearlman G., and Carlson H.E. New medications which decrease levothyroxine absorption. Thyroid 17 (2007) 763-765
40. Siraj E.S., Gupta M.K., and Reddy S.S. Raloxifene causing malabsorption of levothyroxine. Archives of Internal Medicine 163 (2003) 1367-1370
41. Garwood C.L., Van Schepen K.A., McDonough R.P., et al. Increased thyroid-stimulating hormone levels associated with concomitant administration of levothyroxine and raloxifene. Pharmacotherapy 26 (2006) 881-885
42. Sachmechi I., Reich D.M., Aninyei M., et al. Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocrine Practice 13 (2007) 345-349
43. Dietrich J.W., Gieselbrecht K., Holl R.W., et al. Absorption kinetics of levothyroxine is not altered by proton-pump inhibitor therapy. Hormone and Metabolic Research 38 (2006) 57-59
44. Ananthakrishnan S., Braverman L.E., Levin R.M., et al. The effect of famotidine, esomeprazole, and ezetimibe on levothyroxine absorption. Thyroid 18 (2008) 493-498
45. Madhava K., and Hartley A. Hypothyroidism in thyroid carcinoma follow-up: orlistat may inhibit the absorption of thyroxine. [Letter]. Clinical Oncology (Royal College of Radiologists (Great Britain)) 17 (2005) 492